“β-hCG Expression in Patients with Benign and Malignant Cystic Breast Diseases”

Abstract

Background: The most common benign breast lesion in women has been identified for over 150 years as cystic disease of the breast. The relationship between gross cysts and breast cancer is a subject of debate and confusion, but new research indicates that a multidisciplinary study of gross cystic breast disease (GCBD) may be a useful tool for forecasting the complex gross cyst pathology's natural course. Breast fibrocystic disease is believed to be the outcome of an improper histologic reaction to altered hormone levels. It is arguable if this is a legitimate pathophysiologic condition.

Materials & Methods: This study was conducted at private medical college and hospital over a period of 12 months from January 2023 to December 2023. It is a prospective study. Data collected from patients admitted in General surgery department for benign and malignant cystic breast lumps. A total sample of 50 patients.

Results: The most prevalent age bracket is "21 – 30 years," comprising 44% of the total individuals. Following closely behind is the age group "31 – 40 years," representing 30% of the sample. "Benign" has a frequency of 43, which corresponds to 86% of the total sample size. The "Malignant" has a frequency of 7, accounting for 14% of the total sample size.

Conclusion: The findings indicate that elevated levels of breast cystic fluid β-hCG are protective against benign breast cystic illness and that BCF β-hCG levels are helpful in the identification of benign breast cysts.